This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chong, P. Articles by Klein, M. Search for Related Content PubMed PubMed Citation Articles by Chong, P. Articles by Klein, M.

 Previous Article  |  Next Article 

Infect. Immun., 12 1997, 4918-4925, Vol 65, No. 12
Copyright © 1997, American Society for Microbiology

A strategy for rational design of fully synthetic glycopeptide conjugate vaccines

P Chong, N Chan, A Kandil, B Tripet, O James, YP Yang, SP Shi and M Klein
Research Centre, Pasteur Merieux Connaught Canada, North York, Ontario. pchong@ca.pmc-vacc.com

The present study describes a strategy to rationally design fully synthetic glycopeptide conjugate vaccines. Glycopeptide immunogens were constructed by coupling synthetic oligosaccharides comprising repeating units of synthetic 3-beta-D-ribose-(1-1)-D-ribitol-5-phosphate (sPRP) to synthetic peptides containing potent T-helper cell determinants and B-cell epitopes of the Haemophilus influenzae type b (Hib) outer membrane proteins (OMPs) P1, P2, and P6. Rabbit immunogenicity studies revealed that some of these fully synthetic glycoconjugates were capable of eliciting high titers of both anti-PRP and anti-OMP immunoglobulin G antibodies. In addition, we systematically investigated the factors which could influence their immunogenicity. We observed that the magnitude of the anti-PRP antibody response markedly depended on the relative spatial orientation of sPRP and T-cell epitopes, the anti-PRP antibody response was enhanced when a multiple antigenic peptide was used as a carrier, the anti-PRP antibody response was optimal for three PRP repeating units, and lipidation of peptide- PRP conjugates had a minimal effect on the magnitude of the anti-PRP antibody response. The results of this study clearly demonstrate that coupling a carbohydrate hapten to a peptide can provide T-cell help and convert it into a T-cell-dependent antigen. The antisera raised against these conjugates were also found to be protective against Hib infection in the infant rat model of bacteremia.

This article has been cited by other articles:

• Torano, G., Toledo, M. E., Baly, A., Fernandez-Santana, V., Rodriguez, F., Alvarez, Y., Serrano, T., Musachio, A., Hernandez, I., Hardy, E., Rodriguez, A., Hernandez, H., Aguilar, A., Sanchez, R., Diaz, M., Muzio, V., Dfana, J., Rodriguez, M. C., Heynngnezz, L., Verez-Bencomo, V. (2006). Phase I Clinical Evaluation of a Synthetic Oligosaccharide-Protein Conjugate Vaccine against Haemophilus influenzae Type b in Human Adult Volunteers.. CVI 13: 1052-1056 [Abstract] [Full Text]  
• Fernandez-Santana, V., Cardoso, F., Rodriguez, A., Carmenate, T., Pena, L., Valdes, Y., Hardy, E., Mawas, F., Heynngnezz, L., Rodriguez, M. C., Figueroa, I., Chang, J., Toledo, M. E., Musacchio, A., Hernandez, I., Izquierdo, M., Cosme, K., Roy, R., Verez-Bencomo, V. (2004). Antigenicity and Immunogenicity of a Synthetic Oligosaccharide-Protein Conjugate Vaccine against Haemophilus influenzae Type b. Infect. Immun. 72: 7115-7123 [Abstract] [Full Text]  
• Verez-Bencomo, V., Fernandez-Santana, V., Hardy, E., Toledo, M. E., Rodriguez, M. C., Heynngnezz, L., Rodriguez, A., Baly, A., Herrera, L., Izquierdo, M., Villar, A., Valdes, Y., Cosme, K., Deler, M. L., Montane, M., Garcia, E., Ramos, A., Aguilar, A., Medina, E., Torano, G., Sosa, I., Hernandez, I., Martinez, R., Muzachio, A., Carmenates, A., Costa, L., Cardoso, F., Campa, C., Diaz, M., Roy, R. (2004). A Synthetic Conjugate Polysaccharide Vaccine Against Haemophilus influenzae Type b. Science 305: 522-525 [Abstract] [Full Text]  
• Lo-Man, R., Bay, S., Vichier-Guerre, S., Deriaud, E., Cantacuzene, D., Leclerc, C. (1999). A Fully Synthetic Immunogen Carrying a Carcinoma-associated Carbohydrate for Active Specific Immunotherapy1. Cancer Res. 59: 1520-1524 [Abstract] [Full Text]